Navigation Links
Verenium Completes Amendment to 8% Senior Convertible Notes
Date:7/6/2009

>

"The amendments that are effective today are an important first step towards creating a balance sheet for Verenium that can support the capital needs of the Company going forward," said James E. Levine, Chief Financial Officer at Verenium.

The material terms of the exchange are described in more detail in the Company's Current Report on Form 8-K, filed on July 1, 2009 with the Securities and Exchange Commission. This press release is not an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Verenium

Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and animal health markets. The Company possesses integrated, end-to-end capabilities and cutting-edge technology in pre-treatment, novel enzyme development, fermentation and project development for next-generation biofuels. Through a joint venture with BP, the Company is moving rapidly to commercialize its proprietary technology for the production of ethanol from a wide array of non-food feedstocks, including dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.

Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes - proteins that act
'/>"/>

SOURCE Verenium Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
2. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
3. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
4. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
5. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
6. Verenium Reports Financial Results for the First Quarter 2008
7. Verenium Appoints John F. Dee to Board of Directors
8. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
9. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
10. Verenium Corporation to Announce Third Quarter 2008 Financial Results
11. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
(Date:1/14/2014)... Triangle Park, NC (PRWEB) January 14, 2014 ... company focusing on ultra-sensitive POC diagnostic platforms and novel disease ... their first round of financing netting a total of $690,000. ... outside equity capital in the company. This group of private ...
Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
... 11 Alimera Sciences Inc., a privately held,biopharmaceutical ... of prescription ophthalmic pharmaceuticals, today reported,that enrollment has ... safety and efficacy,of Iluvien(TM) in patients with bilateral ... , The ...
... Shareholder Value , , CHICAGO, Dec. ... affiliates, of nearly 29% of the outstanding shares of common stock ... it had delivered a letter to Avigen,s Board of Directors expressing ... value. , , The ...
... today that they continue to penetrate and build market share in ... energy by working with companies like Southwest Windpower, MiaSole, Solyndra, Santur ... ... December 11, 2008 -- DAZ Systems, Inc. , announced today ...
Cached Biology Technology:Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 3Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 4Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 5DAZ Systems, Inc. Thrives in the Clean Energy Industry 2DAZ Systems, Inc. Thrives in the Clean Energy Industry 3
(Date:4/17/2014)... infection , Respiratory syncytial virus (RSV) is ... generating life-threating illness in very young and elderly ... RSV enters host cells through the fusion protein ... Small interfering peptides that prevent bundle formation limit ... highly susceptible to degradation. In this issue of ...
(Date:4/17/2014)... modeling study suggests that fish consumption advisories for ... to long-lived contaminants like persistent organic pollutants (POPs). ... of researchers including University of Toronto Scarborough PhD ... at how different levels of environmental contamination, a ... chemicals in the body influenced exposure in her ...
(Date:4/17/2014)... Our eyes not ... with a continuous stream of information about our own movements. ... a car the world glides by us and leaves ... our brain calculates self-motion from this "optic flow". This way, ... during our own movements. Together with biologists from the University ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Fish consumption advisories fail to cover all types of contaminants 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... patients with epilepsy carry might enable doctors to better ... seizures, suggest basic findings by researchers at the Duke ... the University College London. Patients often undergo a lengthy ... of anti-epilepsy drugs appropriate for them. , The researchers ...
... lymphocytic leukemia (B-CLL),is the most common leukemia in ... mature B lymphocytes in the blood, bone,marrow, and ... early stages,of disease, B-CLL is the result of ... normal B cell death (apoptosis). Livio,Trentin and colleagues ...
... expert manipulators when it comes to co-opting their host's ... from the vast repertoire of proteins and mechanisms dedicated ... like HIV have evolved myriad ways of redirecting that ... eukaryotes have three types of RNA polymerases, each charged ...
Cached Biology News:Gene variations explain drug dose required to control seizures 2Gene variations explain drug dose required to control seizures 3Gene variations explain drug dose required to control seizures 4An HIV Protein Plays a Surprising Role in Gene Activation 2An HIV Protein Plays a Surprising Role in Gene Activation 3